# A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia

> **NCT01435382** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 49 (actual)

## Conditions studied

- Hypercholesterolemia
- Dyslipidemias
- Hyperlipidemias
- Lipid Metabolism Disorders
- Metabolic Diseases

## Interventions

- **BIOLOGICAL:** PF-04950615 (RN316)
- **BIOLOGICAL:** PF-04950615 (RN316)
- **BIOLOGICAL:** PF-04950615 (RN316)
- **BIOLOGICAL:** PF-04950615 (RN316)

## Key facts

- **NCT ID:** NCT01435382
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2012-02
- **Final completion:** 2012-04
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2018-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01435382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01435382, "A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01435382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*